Media headlines about Adamis Pharmaceuticals (NASDAQ:ADMP) have trended somewhat positive on Friday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.9295983533559 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- -$0.19 Earnings Per Share Expected for Adamis Pharmaceuticals Corp (ADMP) This Quarter (americanbankingnews.com)
- Adamis: Wait For It (seekingalpha.com)
- Adamis Pharmaceuticals Corporation (stocksgeeks.com)
- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – Yesterday’s Hot Mover (nasdaqjournal.com)
- Adamis Pharmaceuticals Corp (ADMP) Receives Consensus Rating of “Strong Buy” from Analysts (americanbankingnews.com)
Several research firms recently commented on ADMP. Zacks Investment Research raised shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Maxim Group set a $5.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 19th. B. Riley restated a “buy” rating on shares of Adamis Pharmaceuticals in a research report on Wednesday, March 14th. Finally, Raymond James Financial set a $7.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 23rd. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $6.50.
TRADEMARK VIOLATION WARNING: “Adamis Pharmaceuticals (NASDAQ:ADMP) Given Media Impact Score of 0.08” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/04/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-adamis-pharmaceuticals-admp-stock-price/2030288.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.